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Metabolic bone disease (MBD) of prematurity is an
increasingly well-recognized complication of pre-term
birth. Despite this, there is limited evidence for the opti-
mum method for assessing and monitoring bone health
and appropriate supplementation.
This study assesses the effectiveness of the MBD proto-
col at Monash Health nurseries (Clayton, Dandenong and
Casey) in infants born under 32 weeks’ gestation between
November 2012 and January 2014.
Preliminary data of 93 infants (mean gestational age
(GA) 29 weeks (24-32.3weeks), birth weight (BW) 1279.4g
(553-2512g)) were assessed. Risk factors assessed include
8.8% IUGR infants (n=56), 12.9% maternal pre-eclampsia,
7.5% necrotising enterocolitis (NEC) episodes and expo-
sure to medications as follows:caffeine (84.9%; mean
42 days), diuretics (23.7%; mean 13.8 days) and steroids
(2.2%). Preterm infants received 14.3 days of total parent-
eral nutrition (TPN) on average, with the majority on for-
tified expressed breast milk once enteral feeding was
established.
Initial MBD screen was performed for 80.6% infants
(mean age 36.6 days) with only 24.7% having repeated
monitoring (mean age 67.9 days). 6.5% had Alkaline pho-
phosphatase (ALP) levels >500U/I initially (range 143-
827U/l), reducing to 1.1% (range 173-573U/I). Average
Tubular Resorption of Phosphate (TRP) was 79.7% (n=71).
The majority of infants were on Vitamin D 400units/day.
23.6%(n=22) commenced phosphate supplements (mean
duration 41 days) and 15.1%(n=14) commenced calcium
supplements (mean duration 53.2 days).
Average birth length was 38cm (10-50thcentile) with
evidence of slowing growth velocity (mean follow up
length 49cm (<3rdcentile) at mean age 79.9 days). Five
infants were identified with fractures however two were
from birth trauma and two suspected non-accidental
injury. One patient had an incidental finding of fractured
femur with multiple risk factors for MBD including very
low birth weight (700g), NEC episodes requiring pro-
longed antibiotic therapy (69 days), TPN (48 days),
caffeine (88 days) and diuretic use (22 days).
Significant difference (p<0.001) is noted between
phosphate-treatment and untreated groups for both GA
and BW: Median 27weeks and 929g for treated subjects
versus 29.6weeks and 1343g if untreated. In the phos-
phate-treatment group, ALP levels improved (mean pre-
treatment414U/l and post-treatment264U/l, p=0.0006)
and difference in phosphate levels were also significant
with p=0.003. Between phosphate-treatment group ver-
sus untreated group, differences were insignificant for
ALP (p=0.05) and phosphate levels (p=0.09), though this
may reflect insufficient subsequent MBD screens (treat-
ment group, n=15 versus untreated group, n=7).
Further evaluation is anticipated to help improve MBD
understanding in this high-risk cohort particularly given
morbidity associated with MBD occult fractures. In addi-
tion, secondary outcomes would include cost efficiency of
MBD surveillance and identifying optimal supplemental
therapy.
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